$MEIP News

Last published 1y ago

1y agoMEIP LITSMEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker 'LITS'Business WireLite Strategy Rebrand Aligns with Company's LTC Digital Asset Treasury Strategy Advised by GSR Ventures MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI" or the "Company") today announced that it will change its corporate name to
1y agoMEIPMEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR AdvisingBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP) ("MEI" or "the Company") today announced the acquisition of 929,548 Litecoin (LTC) tokens at an average price of $107.58, successfully launching a major institutional treasury strategy
1y agoMEIPMEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National ExchangeBusiness WireCharlie Lee, the Founder of Litecoin and a lead investor in the PIPE, has joined the Board of Directors of the Company GSR, a preeminent digital asset market maker and lead investor in the private placement, has
1y agoMEIPMEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National ExchangeBusiness WireCharlie Lee, the Founder of Litecoin and a lead investor in the PIPE, will join the Board of Directors of the Company effective upon the closing of the Private Placement GSR, a preeminent digital asset market maker
1y agoMEIPMEI Pharma Reports Second Quarter Fiscal Year 2025 Cash PositionBusiness WireEvaluation of Strategic Alternatives is Ongoing MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the Company is
1y agoMEIPMEI Pharma Reports First Quarter Fiscal Year 2025 Cash PositionBusiness WireReaffirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended September 30, 2024. As previously announced in July 2024,
2y agoMEIPMEI Pharma Reports Fiscal Year End 2024 Cash PositionBusiness WireConfirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company
2y agoMEIPMEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic AlternativesBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today announced that it has engaged Oppenheimer & Co. Inc. to serve as the Company's exclusive financial advisor to assist in its previously announced process to review
2y agoMEIPMEI Pharma to Consider Strategic AlternativesBusiness WireCompany Commences a Cash Preservation Plan Including a Reduction in Force MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today announced that its Board of Directors has determined unanimously to begin evaluation of
2y agoMEIPMEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational HighlightsBusiness Wire-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML
2y agoMEIPMEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344Business Wire– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritizing Measured
2y agoMEIPMEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer PatientsBusiness Wire– Cohort 1 Exceeds Predetermined Non-Progression Threshold in the Ongoing Phase 1b Study – – ME-344 in Combination with Bevacizumab was Generally Well-tolerated with no Evidence of Overlapping Toxicity – – MEI to
2y agoMEIPMEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology ForumBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David Urso,
2y agoMEIPMEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid LeukemiaBusiness Wire– Enrollment Initiated in 12-Patient Expansion Cohort Evaluating Voruciclib Plus Venetoclax in Ongoing Phase 1 Study – – Anti-leukemic Activity Across Multiple Heavily Pretreated Patients Demonstrated Along with
2y agoMEIPMEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational HighlightsBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three
2y agoMEIPMEI Pharma to Present Design of Ongoing Clinical Study Evaluating ME-344 at ASCO GI Cancers Symposium 2024Business Wire– Ongoing Phase 1b Study Evaluating ME-344 Plus Avastin® in Patients with Metastatic Colorectal Cancer: Combination Intended to Create Metabolic Synthetic Lethality – MEI Pharma, Inc. (NASDAQ:MEIP), a
2y agoMEIPMEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib at ASH2023Business Wire– Safety Profile Observed to Date as Monotherapy and in Combination with Venetoclax Suggests no Overlapping Toxicity – – Initial Results from Correlative Studies Demonstrate On-target Reductions in Mcl-1 and RNA Pol
3y agoMEIPMEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational HighlightsBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the
3y agoMEIPMEI Pharma to Present at the Stifel 2023 Healthcare ConferenceBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced it will participate in the Stifel 2023 Healthcare Conference. David Urso, president
3y agoMEIPMEI Pharma Declares Special Cash Dividend of $1.75 Per Share of Common StockBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP) (the "Company"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that pursuant to the previously disclosed cooperation agreement with
3y agoMEIPMEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023Business WireMEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that an abstract highlighting clinical data from the monotherapy dose escalation
3y agoMEIPMEI Pharma Enters into Agreement with Anson Funds and Cable Car CapitalBusiness WireCommits to Capital Return of Up to $3.15 per Share Adds Three New Directors and Forms Capital Allocation Committee of the Board MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") and Anson Funds and Cable Car Capital
3y agoMEIPMEI Pharma Recommends Stockholders Not to ConsentBusiness WireFiles Definitive Consent Revocation Statement Mails Letter to Stockholders Highlighting the Path to Realizing the Full Value of Their MEI Investment Urges Stockholders Not to be Misled by Anson Advisors and Cable
3y agoMEIPAnson and Cable Car Send Letter to MEI Pharma StockholdersGlobeNewswireFile New Definitive Consent Materials to Remove Entire MEI Pharma Board for Cause and Add Advisory Proposal Requesting the Return of Capital to Stockholders Believe Company's Latest Entrenchment Maneuvers Underscore
3y agoMEIPMEI Pharma Adopts Limited-Duration Stockholder Rights PlanBusiness Wire- Responds to Substantial Stock Accumulation by Anson Advisors and Cable Car Capital - - Protects Long-Term Value of All Stockholders' Investments in MEI Pharma - MEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage
3y agoMEIPMEI Pharma Issues Statement Regarding Anson and Cable Car's Opportunistic ActionsBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP) (the "MEI" or "the Company") today issued the following statement in response to the consent solicitation initiated by a group led by Anson Advisors Inc. and Cable Car Capital LLC. The
3y agoMEIPMEI Pharma, Inc. (MEIP) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
3y agoMEIPMEI Pharma Reports Fiscal Year 2023 Results and Operational HighlightsBusiness Wire-- Conference Call Today at 5:00 p.m. Eastern Time -- MEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its fiscal year
3y agoMEIPAnson And Cable Car Send Letter to MEI Pharma StockholdersGlobeNewswireFile Definitive Consent Materials to Remove Entire MEI Pharma Board for Cause Believe Board Reconstitution is Urgently Required to Prevent the Further Destruction of Value and Ensure the Board is Acting in the Best
3y agoMEIPMEI Pharma to Report 2023 Fiscal Year End Financial Results and Provide Corporate Overview on September 26, 2023Business WireMEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the Company will release its 2023 fiscal year end financial results after the
3y agoMEIPMEI Pharma Confirms Receipt of Director Nominations From Anson and Cable CarBusiness WireNo Stockholder Action Required at This Time MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today issued the following statement regarding the nomination of three director candidates by Anson Advisors Inc. and Cable
3y agoMEIPMEI Pharma Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN®) in Patients with Previously Treated Metastatic Colorectal CancerBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the dosing of the first patient in a Phase 1b study evaluating ME-344 in combination
3y agoMEIPMEI Pharma Announces Results of Special Meeting of StockholdersBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today announced that, based on a count of the votes cast at the Company's Special Meeting of Stockholders, MEI, by a narrow margin, did not obtain the necessary stockholder
3y agoINFI MEIPMEI Pharma Reminds Shareholders to Vote Today FOR the Infinity TransactionBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reminded shareholders to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity") in connection with the Company's special
3y agoMEIPMEI Pharma Responds to Anson and Cable CarBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today issued the following statement in response to the Consent Solicitation launched by Anson Advisors Inc. and Cable Car Capital LLC on July 17, 2023: Anson and Cable
3y agoINFI MEIPMEI Pharma Encourages Shareholders to Vote FOR the Infinity TransactionBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today mailed the following letter to shareholders, encouraging them to vote FOR the pending transaction with Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity") in
3y agoMEIPMEI Pharma Postpones Special Meeting of ShareholdersBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today announced that it has postponed its special meeting in connection with the proposed transaction with Infinity Pharmaceuticals, Inc. ("Infinity") to July 23, 2023, at
3y agoINFI MEIPMEI Pharma Provides Final Reminder to Shareholders to Vote Today FOR the Merger With Infinity PharmaceuticalsBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reminded shareholders to vote FOR the Company's pending transaction with Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity") in connection with the upcoming
3y agoINFI MEIPMEI Pharma Reminds Shareholders to Vote FOR the Merger with Infinity PharmaceuticalsBusiness WireGlass Lewis Joins ISS in Recommending that MEI Shareholders Vote FOR the Infinity Transaction MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reminded shareholders to vote FOR the Company's pending transaction
3y agoINFI MEIPISS Recommends Infinity Pharmaceuticals Stockholders Vote FOR the Merger with MEI Pharma, Inc.Business WireInfinity Pharmaceuticals, Inc. (NASDAQ:INFI) ("Infinity"), a clinical-stage biotechnology company developing eganelisib, a potential first-in-class, oral, immuno-oncology macrophage reprogramming drug candidate,
3y agoINFI MEIPMEI Pharma Highlights Recommendation by Leading Independent Proxy Advisory Firm ISS to Vote "FOR" Pending Transaction with Infinity PharmaceuticalsBusiness WireAffirms Value Creating Potential of Proposed Transaction with Infinity Pharmaceuticals Highlights Shareholder Opportunity to Participate in Upside Potential of Diversified Combined Pipeline of Three Clinical-Stage
3y agoINFI MEIPMEI Pharma Mails Letter to Shareholders Reiterating Value Creating Potential of Proposed Transaction with Infinity PharmaceuticalsBusiness WireHighlights Shareholder Opportunity to Participate in Upside Potential of Diversified Combined Pipeline of Three Clinical-Stage Development Programs Combined Company Well-Positioned to Make a Difference in Cancer Care
3y agoMEIPMEI Pharma Responds to Anson and Cable CarBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today issued the following statement in response to the disclosure made today by Anson Advisors Inc. and Cable Car Capital LLC: Anson and Cable Car reiterated their
3y agoINFI MEIPMEI Pharma and Infinity Pharmaceuticals Host Video Webcast Providing Overview and Update on Pending Merger to Advance Three Promising Clinical Oncology CandidatesBusiness WireEvent Available at 8:00 a.m. Eastern Time on June 19, 2023 MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, and Infinity Pharmaceuticals,
3y agoMEIPMEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as SuccessorBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP) (the "Company"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, consistent with the Company's succession planning, Brian
3y agoMEIPMEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as SuccessorBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP) (the "Company"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, in connection with the Company's previously announced
3y agoMEIPMEI Pharma Board of Directors Rejects Unsolicited ProposalBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today announced that its Board of Directors (the "Board") reviewed and rejected the unsolicited and non-binding proposal received on May 23, 2023 from a group represented
3y agoMEIPMEI Pharma Confirms Receipt of Unsolicited Acquisition ProposalBusiness WireMEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today confirmed receipt of an unsolicited and non-binding proposal on May 23, 2023 from a group represented by Anson Advisors Inc. and Cable Car Capital LLC, as referenced
3y agoMEIPMEI Pharma Reports Third Quarter Fiscal Year 2023 Results and Operational HighlightsBusiness Wire-- MEI Begins Fourth Fiscal Quarter with $112.0 Million in Cash -- MEI Pharma, Inc. (NASDAQ:MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for the
3y agoMEIPME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer - NCT05824559ClinicalTrials.govProgression Free Survival (PFS) rate at 16 weeks, Overall Response Rate (ORR), Safety and tolerability of ME-344 administered in combination with bevacizumab